Ki-67预测乳腺癌对新辅助化疗反应的价值

Ki-67 predicting the response to neoadjuvant chemotherapy in breast cancer patients

目的:评价Ki-67在预测乳腺癌对新辅助化疗治疗反应的潜在价值。方法:收集2006年至2013年于本院行乳腺癌根治术,且术前已成功行新辅助化疗者114例。分析乳腺癌患者的临床及免疫组化指标,明确其与新辅助化疗反应的相关关系。结果:4例(4.5%)达到临床完全缓解,86例(75.4%)为临床部分缓解,24例(21.1%)为疾病稳定,尚未发现疾病进展。病理完全缓解为26例(22.8%)。Ki-67是预测乳腺癌病理缓解的独立因素(P=0.027)。根据ROC获得Ki-67预测化疗反应的最佳截断点为25%。结论:高表达Ki-67是预测乳腺癌对新辅助化疗反应的有效指标,其最佳截断点为25%。

Objective： To assess the potential value of Ki-67 in predicting the response to neoadjuvant chemotherapy in breast cancer patients. Methods： One hundred and fourteen breast cancer patients who underwent neoadjuvant therapy prior to surgery between2006 and 2013. Clinical and immunohistochemical factors preoperative were analyzed to determine their correlation with the response to neoadjuvant chemotherapy. Results： Four patients（ 4. 5%） achieved clinical complete response,86 patients（ 75. 4%） in clinical partial response,24 patients（ 21. 2%） in clinical stable disease. Pathological complete response（ p CR） was observed in 26 patients（ 22.8%）. Ki-67 was the only independent predictor of p CR（ P = 0. 027）. ROC analysis showed 25% of Ki-67 would be a reasonable value for predicting the response to chemotherapy. Conclusion： Ki-67 could be an effective item for indicating breast cancer＇s reaction to neoadjuvant chemotherapy,and a reasonable cut-point value for Ki-67 expression level would be 25%.